Issue 7 - The Cancer Letter

<img class="lazy" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%201%201'%3E%3C/svg%3E" data-src="https://cdn.cancerletter.com/media/2021/03/17053004/TCL-logo-horizontal-white.png" alt="" >

Vol.

32

No.

7

July 31, 2009Jul 31, 2009

Free

DOWNLOAD THE PDF

Phase III Trial Of PARP Inhibitor BSI-201 Opens For Triple-Negative Breast Cancer

Studies Shed Light On Racial Disparities Between Blacks, Whites With Breast Cancer

Shorter, Simpler Consent Form Proposed For Phase I Trials

How Much Is Life Worth? The $440 Billion Question

Sunitinib Prolongs Survival In Poor Prognosis, Study Finds

Breast MRI Recipients More Likely To Choose Mastectomy

Opioid Pain Reliever Approved With Risk Reduction Plan

NCI Cooperative Group Clinical Trials Approved

Recent Issues

Volume 52 | Issue 15 - April 17, 2026

Volume 52 | Issue 14 - April 10, 2026

Volume 52 | Issue 13 - April 03, 2026

Volume 52 | Issue 12 - March 27, 2026

Volume 52 | Issue 11 - March 20, 2026

Volume 52 | Issue 10 - March 13, 2026